Cargando…

Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder

Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite...

Descripción completa

Detalles Bibliográficos
Autores principales: Skorobogatov, Katrien, Autier, Valérie, Foiselle, Marianne, Richard, Jean-Romain, Boukouaci, Wahid, Wu, Ching-Lien, Raynal, Sophie, Carbonne, Christel, Laukens, Kris, Meysman, Pieter, Coppens, Violette, le Corvoisier, Philippe, Barau, Caroline, De Picker, Livia, Morrens, Manuel, Tamouza, Ryad, Leboyer, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852293/
https://www.ncbi.nlm.nih.gov/pubmed/36685639
http://dx.doi.org/10.1016/j.bbih.2022.100584
_version_ 1784872595944898560
author Skorobogatov, Katrien
Autier, Valérie
Foiselle, Marianne
Richard, Jean-Romain
Boukouaci, Wahid
Wu, Ching-Lien
Raynal, Sophie
Carbonne, Christel
Laukens, Kris
Meysman, Pieter
Coppens, Violette
le Corvoisier, Philippe
Barau, Caroline
De Picker, Livia
Morrens, Manuel
Tamouza, Ryad
Leboyer, Marion
author_facet Skorobogatov, Katrien
Autier, Valérie
Foiselle, Marianne
Richard, Jean-Romain
Boukouaci, Wahid
Wu, Ching-Lien
Raynal, Sophie
Carbonne, Christel
Laukens, Kris
Meysman, Pieter
Coppens, Violette
le Corvoisier, Philippe
Barau, Caroline
De Picker, Livia
Morrens, Manuel
Tamouza, Ryad
Leboyer, Marion
author_sort Skorobogatov, Katrien
collection PubMed
description Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite levels on diagnosis, clinical state, symptom severity and clinical course in a large French transdiagnostic cohort of SCZ and BD patients. Four patient groups (total n = 507) were included in a cross-sectional observational study: 1) hospitalized acute bipolar patients (n = 205); 2) stable bipolar outpatients (n = 116); 3) hospitalized acute schizophrenia patients (n = 111) and 4) stable schizophrenia outpatients (n = 75), in addition to healthy controls (HC) (n = 185). The quantitative determination of serum kynurenine metabolites was performed using liquid chromatography–tandem mass spectrometry. Kynurenine levels were lower in all patients combined compared to HC while ANCOVA analyses did not reveal inter-diagnostic difference between SCZ and BD. Interestingly, hospitalized patients of both diagnostic groups combined displayed significantly lower kynurenine levels than stabilized outpatients. Psychotic symptoms were associated with lower quinaldic acid (F = 9.18, p=<.001), which is KAT-driven, whereas a longer duration of illness contributed to abnormalities in tryptophan (F = 5.41, p = .023), kynurenine (F = 16.93, p=<.001), xanthurenic acid (F = 9.34, p = .002), quinolinic acid (F = 9.18, p = .003) and picolinic acid (F = 4.15, p = .043), metabolized through the KMO-branch. These data confirm illness state rather than diagnosis to drive KP alterations in SCZ and BD. Lower levels of KP metabolites can thus be viewed as a transdiagnostic feature of SCZ and BD, independently associated with acute symptomatology and a longer duration of illness. Quinaldic acid has seldomly been investigated by previous studies and appears an important state marker in SCZ and BD. As serum samples are used in this study, it is not possible to extrapolate these findings to the brain.
format Online
Article
Text
id pubmed-9852293
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98522932023-01-21 Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder Skorobogatov, Katrien Autier, Valérie Foiselle, Marianne Richard, Jean-Romain Boukouaci, Wahid Wu, Ching-Lien Raynal, Sophie Carbonne, Christel Laukens, Kris Meysman, Pieter Coppens, Violette le Corvoisier, Philippe Barau, Caroline De Picker, Livia Morrens, Manuel Tamouza, Ryad Leboyer, Marion Brain Behav Immun Health Full Length Article Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite levels on diagnosis, clinical state, symptom severity and clinical course in a large French transdiagnostic cohort of SCZ and BD patients. Four patient groups (total n = 507) were included in a cross-sectional observational study: 1) hospitalized acute bipolar patients (n = 205); 2) stable bipolar outpatients (n = 116); 3) hospitalized acute schizophrenia patients (n = 111) and 4) stable schizophrenia outpatients (n = 75), in addition to healthy controls (HC) (n = 185). The quantitative determination of serum kynurenine metabolites was performed using liquid chromatography–tandem mass spectrometry. Kynurenine levels were lower in all patients combined compared to HC while ANCOVA analyses did not reveal inter-diagnostic difference between SCZ and BD. Interestingly, hospitalized patients of both diagnostic groups combined displayed significantly lower kynurenine levels than stabilized outpatients. Psychotic symptoms were associated with lower quinaldic acid (F = 9.18, p=<.001), which is KAT-driven, whereas a longer duration of illness contributed to abnormalities in tryptophan (F = 5.41, p = .023), kynurenine (F = 16.93, p=<.001), xanthurenic acid (F = 9.34, p = .002), quinolinic acid (F = 9.18, p = .003) and picolinic acid (F = 4.15, p = .043), metabolized through the KMO-branch. These data confirm illness state rather than diagnosis to drive KP alterations in SCZ and BD. Lower levels of KP metabolites can thus be viewed as a transdiagnostic feature of SCZ and BD, independently associated with acute symptomatology and a longer duration of illness. Quinaldic acid has seldomly been investigated by previous studies and appears an important state marker in SCZ and BD. As serum samples are used in this study, it is not possible to extrapolate these findings to the brain. Elsevier 2023-01-02 /pmc/articles/PMC9852293/ /pubmed/36685639 http://dx.doi.org/10.1016/j.bbih.2022.100584 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Skorobogatov, Katrien
Autier, Valérie
Foiselle, Marianne
Richard, Jean-Romain
Boukouaci, Wahid
Wu, Ching-Lien
Raynal, Sophie
Carbonne, Christel
Laukens, Kris
Meysman, Pieter
Coppens, Violette
le Corvoisier, Philippe
Barau, Caroline
De Picker, Livia
Morrens, Manuel
Tamouza, Ryad
Leboyer, Marion
Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
title Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
title_full Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
title_fullStr Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
title_full_unstemmed Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
title_short Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
title_sort kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852293/
https://www.ncbi.nlm.nih.gov/pubmed/36685639
http://dx.doi.org/10.1016/j.bbih.2022.100584
work_keys_str_mv AT skorobogatovkatrien kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT autiervalerie kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT foisellemarianne kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT richardjeanromain kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT boukouaciwahid kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT wuchinglien kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT raynalsophie kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT carbonnechristel kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT laukenskris kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT meysmanpieter kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT coppensviolette kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT lecorvoisierphilippe kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT baraucaroline kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT depickerlivia kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT morrensmanuel kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT tamouzaryad kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder
AT leboyermarion kynureninepathwayabnormalitiesarestatespecificbutnotdiagnosisspecificinschizophreniaandbipolardisorder